Your browser doesn't support javascript.
loading
Study of sex-biased differences in genomic profiles in East Asian hepatocellular carcinoma.
Huang, Chung-Yu; Tan, Kien-Thiam; Huang, Shiu-Feng; Lu, Yen-Jung; Wang, Yeh-Han; Chen, Shu-Jen; Tse, Ka-Po.
Affiliation
  • Huang CY; ACT Genomics Co., Ltd., Taipei, Taiwan.
  • Tan KT; ACT Genomics Co., Ltd., Taipei, Taiwan.
  • Huang SF; Anbogen Therapeutics, Inc., Taipei, Taiwan.
  • Lu YJ; Core Pathology Lab, Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
  • Wang YH; ACT Genomics Co., Ltd., Taipei, Taiwan.
  • Chen SJ; ACT Genomics Co., Ltd., Taipei, Taiwan.
  • Tse KP; Department of Pathology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan.
Discov Oncol ; 15(1): 276, 2024 Jul 09.
Article in En | MEDLINE | ID: mdl-38981878
ABSTRACT
Hepatocellular carcinoma (HCC) is characterized by a notable sex disparity in incidence and tumor aggressiveness. Revealing differences in genetic landscapes between male and female HCCs may expand the understanding of sexual disparities mechanisms and assist the development of precision medicine. Although reports on the sex disparity of HCC are accumulated, studies focusing on sex-related biomarkers among Asian populations remain limited. Here, we conducted a comprehensive genomic profiling analysis to explore differences between male and female patients within a cohort of 195 Taiwanese HCC patients. We did not detect any sex-biased genomic alterations. However, when our investigation extended to the TCGA dataset, we found higher frequencies of gene copy gains in CCNE2 and mutations in CTNNB1 and TP53 among male patients. Besides, we further evaluated the associations between genomic alterations and patients' prognosis by sex. The results showed that female patients harboring tumors with STAT3 gain and alterations in the JAK-STAT pathway displayed a poor prognosis. These two factors remained independently associated with unfavorable prognosis even after adjusting for the patient's age and stage characteristics (Hazard ratio = 10.434, 95% CI 3.331-32.677, P < 0.001; Hazard ratio = 2.547, 95% CI 1.195-5.432, P = 0.016, respectively). In summary, this study provides valuable insights into understanding sex disparity in HCC in the East Asian population. Validation through larger cohorts and extensive sequencing efforts is warranted.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Discov Oncol Year: 2024 Type: Article Affiliation country: Taiwan

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Discov Oncol Year: 2024 Type: Article Affiliation country: Taiwan